Nelli R. Nugaeva

Nelli R. Nugaeva

Auto-generated profile, based on publicly available information

Nelli R. Nugaeva

Military Medical Academy named after S.M. Kirov (Moscow Branch) of the Ministry of Defense of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MAMaria D. Ardatskaya
Maria D. Ardatskaya
LBLudmila I. Butorova
Ludmila I. Butorova
MKMarina A. Kalashnikova
Marina A. Kalashnikova
NNNelli R. Nugaeva
Nelli R. Nugaeva
YOYury V. Ovchinnikov
Yury V. Ovchinnikov
ТБТопчий Татьяна Борисовна
Топчий Татьяна Борисовна
Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.

1 January 2022 in Врач
Verified
Journal Article
Closed access
LBL. Butorova
L. Butorova
LKL. Konkova
L. Konkova
VLV. Levin
V. Levin
NNN. Nugaeva
N. Nugaeva
MPM. Palchenkova
M. Palchenkova
ESE. Sayutina
E. Sayutina

5 May 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MAM. D. Ardatskaya
M. D. Ardatskaya
AAA. A. Anuchkin
A. A. Anuchkin
LBL. I. Butorova
L. I. Butorova
APA. I. Pavlov
A. I. Pavlov
NNN. R. Nugayeva
N. R. Nugayeva
ZFZh. V. Fadina
Zh. V. Fadina
Introduction. In recent years, diarrheal syndrome is the most common clinically significant negative effect of the antibiotic therapy (ABT), which constitutes a first-priority medical and social problem. The prescription of any antibiotic for any duration of treatment may cause a potential risk of developing antibiotic-associated diarrhea (AAD). In that regard, there is a need for the systematization of the main pathogenetic aspects of the deveopment of AAD and the rationale for the use of probiotics to prevent its development and treatment. Aim. To conduct a comparative evaluation of the efficacy, adherence and tolerability of a synbiotic Floriosa containing Bifidobacterium lactis Bl-04, Lactobacillus acidophilus La-14, Lactobacillus rhamnosus Lr-32, inulin, B vitamins, and an eubiotic Bifiform containing Enterococcus faecium, Bifidobacterium longum for the prevention of the development of AAD during and after the use of ABT in inpatients. Materials and methods. A total of 60 patients, which was used for the ABT in the hospital settings, were included in the study: the 1st group (30 patients) received a synbiotic, the 2nd group (30 patients) received an eubiotic. The efficacy of the preventive administration of drugs was assessed by Day 12 and 28 of the therapy. The methods included the patients’ assessment of the efficacy and satisfaction with treatment, an assay of short-chain fatty acids (SCFAs) in feces via gas-liquid chromatography and a Clostridium difficile Toxin A + B rapid test. Results. No cases of AAD were detected in both groups. The study drugs were comparable in terms of their efficacy assessment by the doctor and patients. A trend towards a higher assessment of the therapeutic effect and satisfaction with synbiotic therapy was observed. Changes in the absolute and relative content of SCFAs in the patients’ feces from the baseline level were established. More pronounced positive changes in the quantitative and qualitative composition of acids due to the treatment were identified in the patients who received the synbiotic and had more than 3 risk factors. Conclusions. The synbiotic Floriosa and probiotic Bifiform are effective drugs to prevent AAD. The synbiotic has advantages in terms of the overall assessment of the efficacy of the treatment and patient satisfaction, provides a pronounced protective effect on the intestinal microbiocenosis status during and after the ABT (as evidenced by the changes in SCFAs level in the feces), can be the drug of choice for the prevention of AAD, including AAD associated with C. difficile in individuals with more than 3 risk factors for the development of AAD.

8 May 2025 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
MPM. B. Patsenko
M. B. Patsenko
VLV. I. Levin
V. I. Levin
IGI. N. Gaivoronskiy
I. N. Gaivoronskiy
MPM. I. Pugachev
M. I. Pugachev
NGN. I. Gulyaev
N. I. Gulyaev
МПМ. Ю. Паценко
М. Ю. Паценко
Currently, with the abundance of scientific information, specialists face questions in interpreting repolarization disturbances for formulating an electrocardiographic diagnosis. The formulations accepted in domestic electrocardiography methodology, such as “focal changes in the myocardium” for coronary blood flow disorders, and “diffuse changes in the myocardium” for nonspecific repolarization disturbances, are not always related to coronary pathology. Furthermore, there is confusion in interpreting ECG signs of ischemia and/or myocardial damage in coronary pathology. The article reviews modern electrocardiographic criteria for diagnosing primary specific, nonspecific, and secondary repolarization disturbances in the myocardium that are most frequently encountered in clinical practice. The relevance of differential diagnosis of the causes of ST segment depression and elevation, T wave inversion on the ECG is due to the high frequency of pathological conditions underlying them, the difficulty of diagnosis, and significant differences in therapeutic tactics and disease prognosis. Modern concepts of the complex electrophysiological processes occurring in the heart under normal conditions, in myocardial hypertrophy, and at various stages of ischemic heart disease are outlined.The aim of this work is to present current scientific data in the field of interpreting repolarization disturbances on resting ECGs in ischemic heart disease and benign conditions.